Gland Pharma Recommends Final Dividend of ₹20/Share; AGM on Aug 25
Gland Pharma's Board approved Q4 and FY26 results with an unmodified audit opinion. A final dividend of ₹20 per share is recommended. The record date is August 11, 2026. The 48th AGM is scheduled for August 25, 2026.
The announcement includes the approval of financial results and a dividend recommendation, which are material events for shareholders. The AGM date is also provided.
The company announced positive financial results with an unmodified audit opinion and recommended a final dividend, which are generally viewed favorably by investors.
Gland Pharma Limited announced the outcome of its Board Meeting held on May 15, 2026.
The Board approved the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. The statutory auditors issued an unmodified opinion on these results.
The Board has recommended a final dividend of ₹20/- (2000%) per equity share for the financial year 2025-26. This dividend, subject to shareholder approval, will be paid within 30 days of the 48th Annual General Meeting (AGM). The record date for determining eligible shareholders for this dividend is August 11, 2026.
The 48th Annual General Meeting (AGM) of the Company's members is scheduled to be held on August 25, 2026, through video conferencing (VC)/other audio-visual means (OAVM).
The Board Meeting commenced at 15:00 Hrs IST and concluded at 16:10 Hrs IST.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.